Key clinical point: An oral liquid solution of celecoxib, known as DFN-15, is more effective than placebo for the acute treatment of migraine.
Major finding: At 2 hours, pain freedom rates were 35.6% with celecoxib oral solution and 21.7% with placebo. The rates of freedom from the most bothersome symptom were 57.8% with celecoxib oral solution and 44.8% with placebo.
Study details: A randomized, double-blind, placebo-controlled study that included about 600 patients with episodic migraine with or without aura.
Disclosures: The trial was supported by Dr. Reddy’s Laboratories, manufacturer of DFN-15. Two authors are employed by and own stock in Dr. Reddy’s. Other authors disclosed research support from and consulting for Dr. Reddy’s and other companies.
Lipton RB et al. Headache. 2020;60(1):58-70. doi: 10.1111/head.13663.